Medical cannabis and epilepsy in the UK – A qualitative analysis of the carers’ perspective: “We're asking for quality of life for our children”

Abstract

Despite the legalisation of cannabis based medicinal products (CBMPs) in the UK in November 2018, today there remains a scarcity of NHS prescriptions, and many patients continue to face unsustainable financial costs to acquire their medicines. Following on from our previous quantitative study highlighting the effectiveness of CBMPs to treat severe intractable childhood-onset epilepsy, for the present study, we used a narrative, open-ended approach to interview parents/carers of these patients. 11 families were interviewed to understand their current situation in more depth, and to contextualise the previous findings. Although these families have found CBMPs to be the most effective treatment for their child’s condition, access to these medicines remains severely restricted, causing serious challenges in their day-to-day life. Participants discussed a broad range of issues associated with medical cannabis. These included the regulation and policy surrounding medical cannabis, the anger and desperation related to these policies, and the benefits and harms of it. Evidently, the benefits of medical cannabis for these patients far outweigh any associated risks. Many of the issues raised in our study go beyond the science of medical cannabis per se. Rather, they are political issues, related to the wider issue of trust and power in society, and associated challenges of the doctor and patient relationship. The findings highlight the importance of including patients in decision-making about their medical plans and the value that should be given to their reported outcomes and wishes. We conclude by offering implications for further research and for policy making so that these families, and others like them, can finally receive the medications they so urgently require without crippling financial costs.

The Effectiveness and Safety of Medical Cannabis for Treating Cancer Related Symptoms in Oncology Patients

“…Many of the measures that improved are associated with improved quality of life, which may suggest some of the effect of MC treatment on pain intensity was indirect, as previously discussed ( 51 – 53 ). Studies have shown that quality of life in patients that suffer from a severe illness such as cancer plays an important role in treatment adherence and success ( 54 – 56 ).…”

Why doctors have a moral imperative to prescribe and support medical cannabis—an essay by David Nutt

“…Some doctors may have the paternalistic attitude that patients should defer to medical experts rather than discover their own solutions. A recent qualitative study of parents and carers using medical cannabis to treat their child’s epilepsy supports this conclusion, showing the challenging relationship between the doctor (who often lacks specific expertise on medical cannabis) and the parent (who had to develop expertise to be able to treat their child’s condition) 21…”

An Individual’s Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety

“…Hulaihel et al [ 3 ] conducted interviews with a sample of 15 medical cannabis users in Israel who also felt social stigma as a result of taking medical cannabis which negatively impacted their sense and presentation of self. Schlag et al [ 4 ] conducted interviews with 11 families in the UK with children who had been prescribed medical cannabis for epilepsy. The findings from this specific cohort foregrounded frustrations regarding national policy and the regulation of medical cannabis, and challenges experienced due to the lack of knowledge and understanding of medical cannabis within the wider UK healthcare system.…”